(Q41346735)

29 September 2017

1 reference

title

Brofaromine--a review of its pharmacological properties and therapeutic use. (English)

1 reference

29 September 2017

H P Volz

1

1 reference

29 September 2017

C H Gleiter

2

1 reference

29 September 2017

P C Waldmeier

3

1 reference

29 September 2017

M Struck

4

1 reference

29 September 2017

H J Möller

5

1 reference

29 September 2017

language of work or name

1 reference

1 January 1996

1 reference

Journal of Neural Transmission

29 September 2017

published in

1 reference

29 September 2017

volume

103

1 reference

29 September 2017

issue

1-2

1 reference

29 September 2017

page(s)

217-245

1 reference

https://scigraph.springernature.com/pub.10.1007/bf01292628

29 September 2017

exact match

0 references

cites work

Phenelzine v imipramine in atypical depression. A preliminary report

1 reference

https://api.crossref.org/works/10.1007%2FBF01292628

Antidepressant specificity in atypical depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01292628

A double-blind crossover trial of imipramine and phenelzine for outpatients with treatment-refractory depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01292628

Phenelzine versus imipramine in the treatment of probable atypical depression: defining syndrome boundaries of selective MAOI responders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01292628

Phenelzine and imipramine in mood reactive depressives. Further delineation of the syndrome of atypical depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01292628

Atypical depression, panic attacks, and response to imipramine and phenelzine. A replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01292628

Depression subtypes and response to phenelzine, diazepam, and a placebo. Results of a nine hospital collaborative study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01292628

Treatment of imipramine-resistant recurrent depression, IV: A double- blind crossover study of tranylcypromine for anergic bipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01292628

A clinical overview of monoamine oxidase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01292628

Psychopharmacological treatment of social phobia: clinical and biochemical effects of brofaromine, a selective MAO-A inhibitor

21 January 2018

1 reference

12 December 2020

A Canadian multicentre placebo-controlled study of a fixed dose of brofaromine, a reversible selective MAO-A inhibitor, in the treatment of major depression.

1 reference

12 December 2020

Some observations upon a new inhibitor of monoamine oxidase in brain tissue.

1 reference

12 December 2020

Efficacy of reversible inhibitors of monoamine oxidase-A in various forms of depression

1 reference

12 December 2020

Treatment of narcolepsy-cataplexy syndrome with the new selective and reversible MAO-A inhibitor brofaromine-a pilot study.

1 reference

12 December 2020

Selective inhibition of MAO-A, not MAO-B, results in antidepressant-like effects on DRL 72-s behavior

1 reference

12 December 2020

CLINICAL TRIAL OF THE TREATMENT OF DEPRESSIVE ILLNESS. REPORT TO THE MEDICAL RESEARCH COUNCIL BY ITS CLINICAL PSYCHIATRY COMMITTEE

1 reference

12 December 2020

Binding of [3H]brofaromine to monoamine oxidase A in vivo: displacement by clorgyline and moclobemide.

1 reference

12 December 2020

Monoamine oxidase inhibitors in resistant major depression. A double-blind comparison of brofaromine and tranylcypromine in patients resistant to tricyclic antidepressants.

1 reference

12 December 2020

Therapeutic and side-effect profile of a selective and reversible MAO-A inhibitor, brofaromine. Results of dose-finding trials in depressed patients.

1 reference

12 December 2020

Response to phenelzine and imipramine in placebo nonresponders with atypical depression. A new application of the crossover design

1 reference

12 December 2020

Brofaromine in panic disorder: a pilot study with a new reversible inhibitor of monoamine oxidase-A

1 reference

12 December 2020

Displacement of in vivo binding of [3H]brofaromine to rat intestinal monoamine oxidase A by orally administered tyramine

1 reference

12 December 2020

Monoamine oxidase inhibition by phenelzine and brofaromine in healthy volunteers

1 reference

12 December 2020

Beta-phenylethylamine: a specific substrate for type B monoamine oxidase of brain

1 reference

12 December 2020

Monoamine oxidase inhibition by the MAO-A inhibitors brofaromine and clorgyline in healthy volunteers

1 reference

12 December 2020

[Brofaromine--a selective, reversible and short-acting MAO-A inhibitor]

1 reference

12 December 2020

Tricyclic nonresponders: phenomenology and treatment

1 reference

12 December 2020

Localization of monoamine oxidase in rat liver mitochondria

1 reference

12 December 2020

Brofaromine in treatment-resistant depressed patients--a comparative trial versus tranylcypromine.

1 reference

12 December 2020

Effect of the selective MAO-A inhibitors brofaromine, clorgyline and moclobemide on human platelet MAO-B activity

1 reference

12 December 2020

Brofaromine in non-endogenous major depressed inpatients--results of a preliminary dose-finding trial versus tranylcypromine

1 reference

12 December 2020

DIFFERENTIAL RESPONSE OF HOSPITALIZED DEPRESSED PATIENTS TO SOMATIC THERAPY

1 reference

12 December 2020

Characterization of a New, Short-Acting and Specific Inhibitor of Type A Monoamine Oxidase

1 reference

12 December 2020

The monoamine oxidase inhibiting properties of CGP 11305 A.

1 reference

12 December 2020

Newer aspects of the reversible inhibitor of MAO-A and serotonin reuptake, brofaromine

1 reference

12 December 2020

Effects of two different reversible monoamine oxidase-A inhibitors on nociceptive thresholds in the rat

1 reference

12 December 2020

The sleep EEG and nocturnal hormonal secretion studies on changes during the course of depression and on effects of CNS-active drugs.

1 reference

12 December 2020

Brofaromine in elderly major depressed patients--a comparative trial versus imipramine.

1 reference

12 December 2020

The inhibition of monoamine oxidase by brofaromine

1 reference

12 December 2020

Tolerability and antidepressive effect of brofaromine, a short-acting reversible MAO inhibitor — an open study

1 reference

12 December 2020

Adverse reactions to monoamine oxidase inhibitors. Part II. Treatment correlates and clinical management.

1 reference

12 December 2020

Is there a role for selective monoamine oxidase inhibitor therapy in bulimia nervosa? A placebo-controlled trial of brofaromine.

1 reference

12 December 2020

Some puzzling pharmacological effects of monoamine oxidase inhibitors

1 reference

12 December 2020

Monoamine oxidase inhibitors phenelzine and brofaromine increase plasma serotonin and decrease 5-hydroxyindoleacetic acid in patients with major depression: relationship to clinical improvement

1 reference

12 December 2020

Results of an open clinical trial of brofaromine (CGP 11 305 A), a competitive, selective, and short-acting inhibitor of MAO-A in major endogenous depression.

1 reference

12 December 2020

Brofaromine: a monoamine oxidase-A and serotonin uptake inhibitor.

1 reference

12 December 2020

Phenylethylamine-induced stereotypies in the rat: a behavioral test system for assessment of MAO-B inhibitors

1 reference

12 December 2020

Overview of the present state of MAO inhibitors

1 reference

12 December 2020

Reversibility of the interaction of CGP 11305 A with MAO A in vivo

1 reference

12 December 2020

Role of cytochrome P4502D6 in the metabolism of brofaromine. A new selective MAO-A inhibitor

1 reference

12 December 2020

The submitochondrial localization of monoamine oxidase. An enzymatic marker for the outer membrane of rat liver mitochondria

1 reference

12 December 2020

Moclobemide and clomipramine in reactive depression. A placebo-controlled randomized clinical trial

1 reference

12 December 2020

Effects of iproniazid in depressive syndromes.

1 reference

12 December 2020

Potentiation of tyramine pressor responses in conscious rats by reversible inhibitors of monoamine oxidase

1 reference

12 December 2020

Serotonin uptake inhibition by the monoamine oxidase inhibitor brofaromine

1 reference

12 December 2020

Effects of chronic antidepressant treatment on pre- and post-synaptic dopaminergic mechanisms. A short review of the literature and some complementary experiments

1 reference

12 December 2020

Brofaromine (CGP 11 305 A): estimation of plasma concentrations by a biologic technique as compared to liquid chromatography

1 reference

12 December 2020

Classification of Depressed Patients: A Cluster Analysis Derived Grouping

1 reference

12 December 2020

Oral tyramine pressor test and the safety of monoamine oxidase inhibitor drugs: comparison of brofaromine and tranylcypromine in healthy subjects

1 reference

12 December 2020

Brofaromine in major depressed patients: a controlled clinical trial versus imipramine and open follow-up of up to one year

1 reference

12 December 2020

Influence of food on the disposition of the monoamine oxidase-A inhibitor brofaromine in healthy volunteers.

1 reference

12 December 2020

Effects of CGP 11305 A, a new reversible and selective inhibitor of MAO A, on biogenic amine levels and metabolism in the rat brain

1 reference

12 December 2020

Treatment strategy in depression. II. MAO inhibitors in depression resistant to cyclic antidepressants: two controlled crossover studies with tranylcypromine versus L-5-hydroxytryptophan and nomifensine

1 reference

12 December 2020

The reversible MAO inhibitor, brofaromine, inhibits serotonin uptake in vivo

1 reference

12 December 2020

Tyramine potentiation during treatment with MAO inhibitors: brofaromine and moclobemide vs irreversible inhibitors

1 reference

12 December 2020

A European study of views on the use of monoamine oxidase inhibitors

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF01292628

1 reference

Dimensions Publication ID

29 September 2017

1002970669

0 references

1 reference